BigHat Biosciences CSO Peyton Greenside and CEO Mark DePristo
July 20, 2022 10:43 AM EDTUpdated 01:47 PM
Financing
Startups

'Not in to­day's mar­ket': As Am­gen, Bris­tol My­ers back an­ti­body start­up BigHat, bear mar­ket keeps IPO win­dow shut tight

Max Gelman

Senior Editor

A pri­vate an­ti­body start­up is pulling in some new cash to con­tin­ue ad­vanc­ing its dis­cov­ery-stage pro­grams, re­cruit­ing some big back­ers in the process. But in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times